Cangene gold medal award lecture - genomic analysis and modification of Burkholderia cepacia complex bacteriophages

Canadian Journal of Microbiology

Volumn 58, Issue 3, 2012, Pages 221-235

  Lynch, Karlene H ^a   Dennis, Jonathan J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bacteriophage; Burkholderia cepacia complex; Cystic fibrosis; Phage therapy

Indexed keywords

BACTERIAL DISEASE; BACTERIOPHAGE; DISEASE TREATMENT; GENETIC ANALYSIS; GENOMICS; LYSIS; MICROBIAL COMMUNITY; PATHOGENICITY; PUBLIC HEALTH; VIRULENCE;

ARTICLE; BACTERIOPHAGE; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; GENE SEQUENCE; GENETIC ENGINEERING; GENOMICS; NONHUMAN; PRIORITY JOURNAL; VIROTHERAPY;

ANIMALS; BACTERIOPHAGES; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; GENOME, VIRAL; GENOMICS; HUMANS; MICE; OPPORTUNISTIC INFECTIONS; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CEPACIA COMPLEX; NEGIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84857892058     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/W11-135     Document Type: Article

References (145)

1. Aaron, S.D., Ferris, W., Henry, D.A., Speert, D.P., and MacDonald, N. E. 2000. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care Med. 161(4): 1206-1212. PMID:10764313.
2. Ackermann, H.-W. 2007. 5500 phages examined in the electron microscope. Arch. Virol. 152(2): 227-243. doi:10.1007/s00705- 006-0849-1. PMID:17051420.
3. Allison, G.E., and Verma, N.K. 2000. Serotype-converting bacteriophages and O-antigen modification in Shigella flexneri. Trends Microbiol. 8(1): 17-23. doi:10.1016/S0966-842X(99)01646-7.PMID:10637639.
4. Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. 1997. Gapped BLAST and PSIBLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17): 3389-3402. doi:10.1093/nar/25.17. 3389. PMID:9254694.
5. AmpliPhi Biosciences. 2011. Product pipeline [online]. Available from http://www.ampliphibio.com/index.php/pipeline/product_-pipeline [accessed 25 November 2011].
6. Baldwin, A., Mahenthiralingam, E., Drevinek, P., Pope, C., Waine, D. J., Henry, D.A., et al. 2008. Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing. J. Clin. Microbiol. 46(1): 290-295. doi:10.1128/ JCM.01818-07. PMID:18032622.
7. Betley, M.J., and Mekalanos, J.J. 1985. Staphylococcal enterotoxin A is encoded by phage. Science, 229(4709): 185-187. doi:10.1126/ science.3160112. PMID:3160112.
8. Biddick, R., Spilker, T., Martin, A., and LiPuma, J.J. 2003. Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol. Lett. 228(1): 57-62. doi:10.1016/ S0378-1097(03)00724-9. PMID:14612237.
9. Boyd, E.F., and Brüssow, H. 2002. Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol. 10(11): 521-529. doi:10.1016/S0966-842X(02)02459-9. PMID:12419617.
10. Brockhurst, M.A., Buckling, A., and Rainey, P.B. 2005. The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa. Proc. Biol. Sci. 272(1570): 1385-1391. doi:10.1098/rspb.2005.3086. PMID:16006335.
11. Broxmeyer, L., Sosnowska, D., Miltner, E., Chacón, O., Wagner, D., McGarvey, J., et al. 2002. Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent Mycobacterium: a model for phage therapy of intracellular bacterial pathogens. J. Infect. Dis. 186(8): 1155-1160. doi:10.1086/343812. PMID:12355367.
12. Brüssow, H., and Desiere, F. 2001. Comparative phage genomics and the evolution of Siphoviridae: insights from dairy phages. Mol. Microbiol. 39(2): 213-222. doi:10.1046/j.1365-2958.2001.02228. x. PMID:11136444.
13. Brüssow, H. 2001. Phages of dairy bacteria. Annu. Rev. Microbiol. 55: 283-303. PMID:11544357.
14. Burkholder, W.H. 1950. Sour skin, a bacterial rot of onion bulbs. Phytopathology, 40(1): 115-117.
15. Burns, J.L., Jonas, M., Chi, E.Y., Clark, D.K., Berger, A., and Griffith, A. 1996. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect. Immun. 64(10): 4054-4059. PMID:8926068.
16. Cady, K.C., White, A.S., Hammond, J.H., Abendroth, M.D., Karthikeyan, R.S.G., Lalitha, P., et al. 2011. Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates. Microbiology, 157(2): 430-437. doi:10.1099/mic.0.045732-0. PMID:21081758.
17. Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., and Iannelli, D. 2007. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 51(8): 2765-2773. doi:10.1128/AAC.01513-06. PMID:17517843.
18. Carmody, L.A., Gill, J.J., Summer, E.J., Sajjan, U.S., Gonzalez, C.F., Young, R.F., and LiPuma, J.J. 2010. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201(2): 264-271. doi:10.1086/649227. PMID:20001604.
19. Casjens, S.R. 2005. Comparative genomics and evolution of the tailed-bacteriophages. Curr. Opin. Microbiol. 8(4): 451-458. doi:10.1016/j.mib.2005.06.014. PMID:16019256.
20. Chakraborty, S., Waise, T.M.Z., Hassan, F., Kabir, Y., Smith, M.A., and Arif, M. 2009. Assessment of the evolutionary origin and possibility of CRISPR-Cas (CASS) mediated RNA interference pathway in Vibrio cholerae O395. In Silico Biol. 9(4): 245-254. PMID:20109154.
21. Cihlar, R.L., Lessie, T.G., and Holt, S.C. 1978. Characterization of bacteriophage CP1, an organic solvent sensitive phage associated with Pseudomonas cepacia. Can. J. Microbiol. 24(11): 1404-1412. doi:10.1139/m78-224. PMID:743648.
22. Clokie, M.R.J., and Mann, N.H. 2006. Marine cyanophages and light. Environ. Microbiol. 8(12): 2074-2082. doi:10.1111/j.1462-2920. 2006.01171.x. PMID:17107549.
23. Coenye, T., Mahenthiralingam, E., Henry, D., LiPuma, J.J., Laevens, S., Gillis, M., et al. 2001. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int. J. Syst. Evol. Microbiol. 51(4): 1481-1490. PMID:11491349.
24. Croucher, N.J., and Thomson, N.R. 2010. Studying bacterial transcriptomes using RNA-seq. Curr. Opin. Microbiol. 13(5): 619-624. doi:10.1016/j.mib.2010.09.009. PMID:20888288.
25. Cystic Fibrosis Canada. 2011a. Cystic fibrosis in Canada [online]. Available from http://www.cysticfibrosis.ca/assets/files/pdf/Cystic_fibrosis_in_canadaE.pdf [accessed 25 November 2011].
26. Cystic Fibrosis Canada. 2011b. Canadian cystic fibrosis patient data registry report 2009 [online]. Available from http://www.cysticfibrosis.ca/assets/files/pdf/CPDR_ReportE.pdf [accessed 25 November 2011].
27. Cystic Fibrosis Canada. 2011c. Infection control and cystic fibrosis [online]. Available from http://www.cysticfibrosis.ca/assets/files/pdf/Infection_Control_and_CFE.pdf [accessed 25 November 2011].
28. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. 2003. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2): 151-185. doi:10.1016/S0167-6296(02)00126-1. PMID:12606142.
29. Donlan, R.M. 2009. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 17(2): 66-72. doi:10.1016/j.tim.2008.11.002. PMID:19162482.
30. Festini, F., Buzzetti, R., Bassi, C., Braggion, C., Salvatore, D., Taccetti, G., and Mastella, G. 2006. Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review. J. Hosp. Infect. 64(1): 1-6. doi:10. 1016/j.jhin.2006.02.021. PMID:16835001.
31. Fothergill, J.L., Mowat, E., Walshaw, M.J., Ledson, M.J., James, C. E., and Winstanley, C. 2011. Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55(1): 426-428. doi:10.1128/AAC.01257-10. PMID:20974862.
32. Freeman, V.J. 1951. Studies on the virulence of bacteriophageinfected strains of Corynebacterium diphtheriae. J. Bacteriol. 61(6): 675-688.PMID:14850426.
33. Gill, J.J., Summer, E.J., Russell, W.K., Cologna, S.M., Carlile, T.M., Fuller, A.C., et al. 2011. Genome and characterization of phages Bcep22 and BcepIL02, founders of a novel phage type in Burkholderia cenocepacia. J. Bacteriol. 193(19): 5300-5313. doi:10.1128/JB.05287-11. PMID:21804006.
34. Gillis, M., Van Van, T., Bardin, R., Goor, M., Hebbar, P., Willems, A., et al. 1995. Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp. nov. for N2-fixing isolates from rice in Vietnam. Int. J. Syst. Bacteriol. 45(2): 274-289. doi:10.1099/00207713-45-2-274.
35. Goerke, C., Papenberg, S.M.Y., Dasbach, S., Dietz, K., Ziebach, R., Kahl, B.C., and Wolz, C. 2004. Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. J. Infect. Dis. 189(4): 724-734. doi:10.1086/381502. PMID:14767828.
36. Golshahi, L., Seed, K.D., Dennis, J.J., and Finlay, W.H. 2008. Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J. Aerosol Med. Pulm. Drug Deliv. 21(4): 351-359.
37. Golshahi, L., Lynch, K.H., Dennis, J.J., and Finlay, W.H. 2011. In vitro lung delivery of bacteriophages KS4-M and FKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl.Microbiol. 110(1): 106-117. doi:10.1111/j.1365-2672.2010. 04863.x. PMID:20875034.
38. Goudie, A.D., Lynch, K.H., Seed, K.D., Stothard, P., Shrivastava, S., Wishart, D.S., and Dennis, J.J. 2008. Genomic sequence and activity of KS10, a transposable phage of the Burkholderia cepacia complex. BMC Genomics, 9(1): 615. doi:10.1186/1471- 2164-9-615. PMID:19094239.
39. Govan, J.R.W., Hughes, J.E., and Vandamme, P. 1996. Burkholderia cepacia: medical, taxonomic and ecological issues. J. Med. Microbiol. 45(6): 395-407. doi:10.1099/00222615-45-6-395. PMID:8958242.
40. Griffiths, A.J.F., Miller, J.H., Suzuki, D.T., Lewontin, R.C., and Gelbart, W.M. 2000. An introduction to genetic analysis. W.H. Freeman and Company, New York.
41. Grimwood, K., Kidd, T.J., and Tweed, M. 2009. Successful treatment of cepacia syndrome. J. Cyst. Fibros. 8(4): 291-293. doi:10.1016/ j.jcf.2009.04.002. PMID:19411195.
42. Grissa, I., Vergnaud, G., and Pourcel, C. 2007. The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats. BMC Bioinformatics, 8(1): 172. doi:10.1186/1471-2105-8-172. PMID:17521438.
43. Guo, L., Lim, K.B., Poduje, C.M., Daniel, M., Gunn, J.S., Hackett, M., and Miller, S.I. 1998. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell, 95(2): 189-198. doi:10.1016/S0092-8674(00)81750-X. PMID:9790526.
44. Hagens, S., and Bläsi, U. 2003. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett. Appl. Microbiol.37(4): 318-323. doi:10.1046/j.1472-765X.2003.01400.x. PMID: 12969496.
45. Hagens, S., Habel, A., Von Ahsen, U., Von Gabain, A., and Bläsi, U. 2004. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48(10): 3817-3822. doi:10.1128/AAC.48.10.3817- 3822.2004. PMID:15388440.
46. Hanlon, G.W., Denyer, S.P., Olliff, C.J., and Ibrahim, L.J. 2001. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol. 67(6): 2746-2753. doi:10.1128/AEM.67.6.2746-2753.2001. PMID:11375190.
47. Harper, D.R., and Enright, M.C. 2011. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J. Appl. Microbiol. 111(1): 1-7. doi:10.1111/j.1365-2672.2011.05003.x.PMID:21410851.
48. Hatfull, G.F. 2010. Mycobacteriophages: genes and genomes. Annu.Rev. Microbiol. 64(1): 331-356. doi:10.1146/annurev.micro. 112408.134233. PMID:20528690.
49. Hatfull, G.F., and Hendrix, R.W. 2011. Bacteriophages and their genomes. Curr. Opin. Virol. 1(4): 298-303. doi:10.1016/j.coviro. 2011.06.009. PMID:22034588.
50. Häusler, T. 2006. Viruses vs. superbugs: A solution to the antibiotics crisis? Macmillan, New York.
51. Henn, M.R., Sullivan, M.B., Stange-Thomann, N., Osburne, M.S., Berlin, A.M., Kelly, L., et al. 2010. Analysis of high-throughput sequencing and annotation strategies for phage genomes. PLoS ONE, 5(2): e9083. doi:10.1371/journal.pone.0009083. PMID:20140207.
52. Hens, D.K., Ghosh, A.N., and Kumar, R. 2005. A new small temperate DNA phage BcP15 isolated from Burkholderia cepacia DR11. Arch. Virol. 150(12): 2421-2428. doi:10.1007/s00705- 005-0601-2. PMID:16052281.
53. Holden, M.T.G., Titball, R.W., Peacock, S.J., Cerdeño-Tárraga, A.M., Atkins, T., Crossman, L.C., et al. 2004. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl. Acad. Sci. U.S.A. 101(39): 14240-14245. doi:10.1073/pnas.0403302101. PMID:15377794.
54. Holden, M.T.G., Seth-Smith, H.M.B., Crossman, L.C., Sebaihia, M., Bentley, S.D., Cerdeño-Tárraga, A.M., et al. 2009. The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J. Bacteriol. 191(1): 261-277. doi:10.1128/JB. 01230-08. PMID:18931103.
55. Isles, A., Maclusky, I., Corey, M., Gold, R., Prober, C., Fleming, P., and Levison, H. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J. Pediatr. 104(2): 206-210. doi:10.1016/S0022-3476(84)80993-2. PMID:6420530.
56. Jones, A.M., Dodd, M.E., Govan, J.R.W., Barcus, V., Doherty, C.J., Morris, J., and Webb, A.K. 2004. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax, 59(11): 948-951. doi:10.1136/thx.2003.017210. PMID: 15516469.
57. Juncker, A.S., Willenbrock, H., Von Heijne, G., Brunak, S., Nielsen, H., and Krogh, A. 2003. Prediction of lipoprotein signal peptides in gram-negative bacteria. Protein Sci. 12(8): 1652-1662. doi:10.1110/ps.0303703. PMID:12876315.
58. Kawasaki, K., Ernst, R.K., and Miller, S.I. 2004. Deacylation and palmitoylation of lipid A by Salmonellae outer membrane enzymes modulate host signaling through Toll-like receptor 4. J. Endotoxin Res. 10(6): 439-444. PMID:15588428.
59. Kelly, D., McAuliffe, O., Ross, R.P., O'Mahony, J., and Coffey, A. 2011. Development of a broad-host-range phage cocktail for biocontrol. Bioeng. Bugs, 2(1): 31-37. doi:10.4161/bbug.2.1.13657. PMID:21636985.
60. Kennedy, M.P., Coakley, R.D., Donaldson, S.H., Aris, R.M., Hohneker, K., Wedd, J.P., et al. 2007. Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center. J. Cyst. Fibros. 6(4): 267-273. doi:10.1016/j.jcf.2006.10.007. PMID:17137846.
61. Kropinski, A.M. 2006. Phage therapy - everything old is new again. Can. J. Infect. Dis.Med.Microbiol. 17(5): 297-306. PMID:18382643.
62. Langley, R., Kenna, D.T., Vandamme, P., Ure, R., and Govan, J.R.W. 2003. Lysogeny and bacteriophage host range within the Burkholderia cepacia complex. J. Med. Microbiol. 52(6): 483-490. doi:10.1099/jmm.0.05099-0. PMID:12748267.
63. Langley, R.J., Kenna, D., Bartholdson, J., Campopiano, D.J., and Govan, J.R.W. 2005. Temperate bacteriophages DK4 and BcepMu from Burkholderia cenocepacia J2315 are identical. FEMS Immunol. Med. Microbiol. 45(2): 349-350. doi:10.1016/j. femsim.2005.06.001. PMID:16009540.
64. Lavigne, R., Seto, D., Mahadevan, P., Ackermann, H.-W., and Kropinski, A.M. 2008. Unifying classical and molecular taxonomic classification: analysis of the Podoviridae using BLASTPbased tools. Res. Microbiol. 159(5): 406-414. doi:10.1016/j. resmic.2008.03.005. PMID:18555669.
65. Lavigne, R., Darius, P., Summer, E.J., Seto, D., Mahadevan, P., Nilsson, A.S., et al. 2009. Classification of Myoviridae bacteriophages using protein sequence similarity. BMC Microbiol. 9(1): 224. doi:10.1186/1471-2180-9-224. PMID:19857251.
66. Levin, B.R., and Bull, J.J. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2(2): 166-173.doi:10.1038/nrmicro822. PMID:15040264.
67. LiPuma, J.J., Dasen, S.E., Stull, T.L., Nielson, D.W., and Stern, R.C. 1990. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet, 336(8723): 1094-1096. doi:10.1016/0140-6736(90)92571-X. PMID:1977981.
68. Loutet, S.A., Flannagan, R.S., Kooi, C., Sokol, P.A., and Valvano, M. A. 2006. A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J. Bacteriol. 188(6): 2073-2080. doi:10.1128/JB.188.6.2073-2080.2006. PMID:16513737.
69. Lu, T.K., and Collins, J.J. 2007. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U.S.A. 104(27): 11197-11202. doi:10.1073/pnas.0704624104. PMID:17592147.
70. Lu, T.K., and Collins, J.J. 2009. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U.S.A. 106(12): 4629-4634. doi:10.1073/pnas. 0800442106. PMID:19255432.
71. Lukashin, A.V., and Borodovsky, M. 1998. GeneMark.hmm: new solutions for gene finding. Nucleic Acids Res. 26(4): 1107-1115. doi:10.1093/nar/26.4.1107. PMID:9461475.
72. Lynch, K.H., and Dennis, J.J. 2008. Development of a speciesspecific fur gene-based method for identification of the Burkholderia cepacia complex. J. Clin. Microbiol. 46(2): 447-455. doi:10.1128/JCM.01460-07. PMID:18057135.
73. Lynch, K.H., Seed, K.D., Stothard, P., and Dennis, J.J. 2010a. Inactivation of Burkholderia cepacia complex phage KS9 gp41 identifies the phage repressor and generates lytic virions. J. Virol. 84(3): 1276-1288. doi:10.1128/JVI.01843-09. PMID:19939932.
74. Lynch, K.H., Stothard, P., and Dennis, J.J. 2010b. Genomic analysis and relatedness of P2-like phages of the Burkholderia cepacia complex. BMC Genomics, 11(1): 599. doi:10.1186/1471-2164- 11-599. PMID:20973964.
75. Lynch, K.H., Stothard, P., and Dennis, J.J. 2012. Characterization of DC1, a broad-host-range Bcep22-like podovirus. Appl. Environ. Microbiol. 78(3): 889-891. doi:10.1128/AEM.07097-11. PMID: 22139000.
76. Mahenthiralingam, E., Urban, T.A., and Goldberg, J.B. 2005. The multifarious, multireplicon Burkholderia cepacia complex. Nat. Rev. Microbiol. 3(2): 144-156. doi:10.1038/nrmicro1085. PMID: 15643431.
77. Mahenthiralingam, E., Song, L., Sass, A., White, J., Wilmot, C., Marchbank, A., et al. 2011. Enacyloxins are products of an unusual hybrid modular polyketide synthase encoded by a cryptic Burkholderia ambifaria genomic island. Chem. Biol. 18(5): 665-677. doi:10.1016/j.chembiol.2011.01.020. PMID:21609847.
78. Makarova, K.S., Haft, D.H., Barrangou, R., Brouns, S.J.J., Charpentier, E., Horvath, P., et al. 2011. Evolution and classification of the CRISPR-Cas systems. Nat. Rev. Microbiol. 9(6): 467-477. doi:10. 1038/nrmicro2577. PMID:21552286.
79. Marchler-Bauer, A., and Bryant, S.H. 2004. CD-Search: protein domain annotations on the fly. Nucleic Acids Res. 32(Web Server issue): W327-W331. doi:10.1093/nar/gkh454. PMID:15215404.
80. Matinkhoo, S., Lynch, K.H., Dennis, J.J., Finlay, W.H., and Vehring, R. 2011. Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 100(12): 5197-5205. doi:10.1002/jps.22715. PMID:22020816.
81. Matsuda, T., Freeman, T.A., Hilbert, D.W., Duff, M., Fuortes, M., Stapleton, P.P., and Daly, J.M. 2005. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery, 137 (6): 639-646. doi:10.1016/j.surg.2005.02.012. PMID:15933632.
82. Matsumoto, H., Itoh, Y., Ohta, S., and Terawaki, Y. 1986. A generalized transducing phage of Pseudomonas cepacia. J. Gen. Microbiol. 132(9): 2583-2586.PMID:3794654.
83. Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., et al. 2003. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phiMR11. J. Infect. Dis. 187(4): 613-624. doi:10.1086/374001. PMID:12599078.
84. McIntyre, K., Muller, M., Ota, S., Stephenson, A., and Tullis, E. 2009. Epidemic of Burkholderia cenocepacia ET12 in Toronto adult cystic fibrosis clinic: lessons learned. In Proceedings of the International Burkholderia cepacia Working Group 13th Annual Meeting. Abstr. V-c.
85. McNeely, D., Moore, J.E., Elborn, J.S., Millar, B.C., Rendall, J., and Dooley, J.S. 2009. Isolation of Burkholderia cenocepacia and Burkholderia vietnamiensis from human sewage. Int. J. Environ. Health Res. 19(2): 157-162. doi:10.1080/09603120802392876. PMID:19370465.
86. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE, 4(3): e4944. doi:10.1371/ journal.pone.0004944. PMID:19300511.
87. Merril, C.R., Scholl, D., and Adhya, S.L. 2003. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2(6): 489-497. doi:10.1038/nrd1111. PMID:12776223.
88. Moon, S., Byun, Y., Kim, H.-J., Jeong, S., and Han, K. 2004. Predicting genes expressed via -1 and +1 frameshifts. Nucleic Acids Res. 32(16): 4884-4892. doi:10.1093/nar/gkh829. PMID: 15371551.
89. Nakayama, K., Kanaya, S., Ohnishi, M., Terawaki, Y., and Hayashi, T. 1999. The complete nucleotide sequence of FCTX, a cytotoxinconverting phage of Pseudomonas aeruginosa: implications for phage evolution and horizontal gene transfer via bacteriophages. Mol. Microbiol. 31(2): 399-419. doi:10.1046/j.1365-2958.1999. 01158.x. PMID:10027959.
90. Nzula, S., Vandamme, P., and Govan, J.R.W. 2000. Sensitivity of the Burkholderia cepacia complex and Pseudomonas aeruginosa to transducing bacteriophages. FEMS Immunol. Med. Microbiol. 28(4): 307-312. doi:10.1111/j.1574-695X.2000.tb01491.x. PMID:10891654.
91. Nzula, S., Vandamme, P., and Govan, J.R.W. 2002. Infuence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J. Antimicrob. Chemother. 50(2): 265-269. doi:10.1093/jac/dkf137. PMID:12161410.
92. Ohtsubo, Y., Genka, H., Komatsu, H., Nagata, Y., and Tsuda, M. 2005. High-temperature-induced transposition of insertion elements in Burkholderia multivorans ATCC 17616. Appl. Environ. Microbiol. 71(4): 1822-1828. doi:10.1128/AEM.71.4.1822-1828. 2005. PMID:15812007.
93. Palmer, K.L., and Gilmore, M.S. 2010. Multidrug-resistant enterococci lack CRISPR-cas. mBio, 1(4): e00227-10-e00227-19. doi:10.1128/mBio.00227-10.
94. Paul, V.D., Sundarrajan, S., Rajagopalan, S.S., Hariharan, S., Kempashanaiah, N., Padmanabhan, S., et al. 2011. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol. 11(1): 195. doi:10.1186/1471-2180- 11-195. PMID:21880144.
95. Peeters, E., Nelis, H.J., and Coenye, T. 2009. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. J. Antimicrob. Chemother. 64(4): 801-809. doi:10.1093/jac/dkp253. PMID: 19633000.
96. Pouillot, F., Blois, H., and Iris, F. 2010. Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. Biosecur. Bioterror. 8(2): 155-169. doi:10. 1089/bsp.2009.0057. PMID:20569057.
97. Pujol, M., Corbella, X., Carratala, J., and Gudiol, F. 1992. Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin. Infect. Dis. 15(5): 887-888. doi:10.1093/clind/15.5.887. PMID:1280168.
98. Ramasubbu, N., Thomas, L.M., Ragunath, C., and Kaplan, J.B. 2005. Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen Actinobacillus actinomycetemcomitans. J. Mol. Biol. 349(3): 475-486. doi:10.1016/j.jmb. 2005.03.082. PMID:15878175.
99. Rhoads, D.D., Wolcott, R.D., Kuskowski, M.A., Wolcott, B.M., Ward, L.S., and Sulakvelidze, A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care, 18(6): 237-238, 240-243.PMID:19661847.
100. Rice, S.A., Tan, C.H., Mikkelsen, P.J., Kung, V., Woo, J., Tay, M., et al. 2009. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J. 3(3): 271-282. doi:10.1038/ismej.2008.109. PMID:19005496.
101. Rich, D.P., Anderson, M.P., Gregory, R.J., Cheng, S.H., Paul, S., Jefferson, D.M., et al. 1990. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature, 347(6291): 358-363. doi:10.1038/347358a0. PMID:1699126.
102. Riedel, K., Hentzer, M., Geisenberger, O., Huber, B., Steidle, A., Wu, H., et al. 2001. N-Acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology, 147(12): 3249-3262.PMID: 11739757.
103. Robinson, M., and Bye, P.T.B. 2002. Mucociliary clearance in cystic fibrosis. Pediatr. Pulmonol. 33(4): 293-306. doi:10.1002/ppul. 10079. PMID:11921459.
104. Rolain, J.M., François, P., Hernandez, D., Bittar, F., Richet, H., Fournous, G., et al. 2009. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol. Direct, 4: 1. doi:10.1186/1745- 6150-4-1. PMID:19144117.
105. Ronning, C.M., Losada, L., Brinkac, L., Inman, J., Ulrich, R.L., Schell, M., et al. 2010. Genetic and phenotypic diversity in Burkholderia: contributions by prophage and phage-like elements. BMC Microbiol. 10(1): 202. doi:10.1186/1471-2180-10-202. PMID:20667135.
106. Routier, S.J.M. 2010. DC1, a podoviridae with a putative cepacian depolymerase enzyme. M.Sc. thesis, University of Alberta, Edmonton, Alta., Canada.
107. Ryley, H.C., and Doull, I.J.M. 2003. Burkholderia cepacia complex infection in patients with cystic fibrosis: laboratory investigations, epidemiology and clinical management. Rev. Med. Microbiol. 14(1): 15-24.
108. Saini, L.S., Galsworthy, S.B., John, M.A., and Valvano, M.A. 1999. Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation. Microbiology, 145(12): 3465-3475.PMID:10627044.
109. Sakaguchi, Y., Hayashi, T., Kurokawa, K., Nakayama, K., Oshima, K., Fujinaga, Y., et al. 2005. The genome sequence of Clostridium botulinum type C neurotoxin-converting phage and the molecular mechanisms of unstable lysogeny. Proc. Natl. Acad. Sci. U.S.A. 102(48): 17472 -17477. doi:10.1073/pnas.0505503102. PMID: 16287978.
110. Schattner, P., Brooks, A.N., and Lowe, T.M. 2005. The tRNAscan- SE, snoscan and snoGPS web servers for the detection of tRNAs and snoRNAs. Nucleic Acids Res. 33(Web Server issue): W686-W689. doi:10.1093/nar/gki366. PMID:15980563.
111. Schell, M.A., Lipscomb, L., and DeShazer, D. 2008. Comparative genomics and an insect model rapidly identify novel virulence genes of Burkholderia mallei. J. Bacteriol. 190(7): 2306-2313. doi:10.1128/JB.01735-07. PMID:18223084.
112. Seed, K.D., and Dennis, J.J. 2005. Isolation and characterization of bacteriophages of the Burkholderia cepacia complex. FEMS Microbiol. Lett. 251(2): 273-280. doi:10.1016/j.femsle.2005.08. 011. PMID:16140471.
113. Seed, K.D., and Dennis, J.J. 2009. Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob. Agents Chemother. 53(5): 2205-2208. doi:10.1128/AAC.01166-08. PMID:19223640.
114. Segal, B.H., Leto, T.L., Gallin, J.I., Malech, H.L., and Holland, S.M. 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine, 79(3): 170-200. doi:10.1097/ 00005792-200005000-00004. PMID:10844936.
115. Semler, D.D., Lynch, K., and Dennis, J.J. 2012. The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections. Front. Cell. Inf. Microbio. 1: 27. doi:10.3389/ fcimb.2011.00027.
116. Shah, S.A., and Garrett, R.A. 2011. CRISPR/Cas and Cmr modules, mobility and evolution of adaptive immune systems. Res. Microbiol. 162(1): 27-38. doi:10.1016/j.resmic.2010.09.001. PMID:20863886.
117. Smith, H.W., and Huggins, M.B. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128(2): 307-318.PMID:7042903.
118. Soothill, J., Hawkins, C., and Harper, D. 2011. Bacteriophagecontaining therapeutic agents. Patent US 2011/0020290 A1.
119. Söding, J., Biegert, A., and Lupas, A.N. 2005. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res. 33(Web Server issue): W244-W248. doi:10.1093/nar/gki408. PMID:15980461.
120. Speert, D.P., Henry, D., Vandamme, P., Corey, M., and Mahenthiralingam, E. 2002. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg. Infect. Dis. 8(2): 181-187.PMID:11897071.
121. Stewart, F.M., and Levin, B.R. 1984. The population biology of bacterial viruses: why be temperate. Theor. Popul. Biol. 26(1): 93-117. doi:10.1016/0040-5809(84)90026-1. PMID:6484871.
122. Summer, E.J. 2009. Preparation of a phage DNA fragment library for whole genome shotgun sequencing. Methods Mol. Biol. 502: 27-46. doi:10.1007/978-1-60327-565-1_4. PMID:19082550.
123. Summer, E.J., Gonzalez, C.F., Carlisle, T., Mebane, L.M., Cass, A. M., Savva, C.G., et al. 2004. Burkholderia cenocepacia phage BcepMu and a family of Mu-like phages encoding potential pathogenesis factors. J. Mol. Biol. 340(1): 49-65. doi:10.1016/j. jmb.2004.04.053. PMID:15184022.
124. Summer, E.J., Gonzalez, C.F., Bomer, M., Carlile, T., Embry, A., Kucherka, A.M., et al. 2006. Divergence and mosaicism among virulent soil phages of the Burkholderia cepacia complex. J. Bacteriol. 188(1): 255-268. doi:10.1128/JB.188.1.255-268.2006. PMID:16352842.
125. Summer, E.J., Gill, J.J., Upton, C., Gonzalez, C.F., and Young, R. 2007a. Role of phages in the pathogenesis of Burkholderia, or 'Where are the toxin genes in Burkholderia phages?'. Curr. Opin. Microbiol. 10(4): 410-417. doi:10.1016/j.mib.2007.05.016. PMID:17719265.
126. Summer, E.J., Berry, J., Tran, T.A.T., Niu, L., Struck, D.K., and Young, R. 2007b. Rz/Rz1 lysis gene equivalents in phages of Gram-negative hosts. J. Mol. Biol. 373(5): 1098-1112. doi:10. 1016/j.jmb.2007.08.045. PMID:17900620.
127. Taplin, D., Bassett, D.C.J., and Mertz, P.M. 1971. Foot lesions associated with Pseudomonas cepacia. Lancet, 2(7724): 568-571.PMID:4106104.
128. Thiel, K. 2004. Old dogma, new tricks-21st century phage therapy. Nat. Biotechnol. 22(1): 31-36. doi:10.1038/nbt0104-31. PMID: 14704699.
129. van der Oost, J., Jore, M.M., Westra, E.R., Lundgren, M., and Brouns, S.J.J. 2009. CRISPR-based adaptive and heritable immunity in prokaryotes. Trends Biochem. Sci. 34(8): 401-407. doi:10.1016/j.tibs.2009.05.002. PMID:19646880.
130. Vandamme, P., and Dawyndt, P. 2011. Classification and identification of the Burkholderia cepacia complex: past, present and future. Syst. Appl. Microbiol. 34(2): 87-95. doi:10.1016/j.syapm.2010. 10.002. PMID:21257278.
131. Vandamme, P., Holmes, B., Vancanneyt, M., Coenye, T., Hoste, B., Coopman, R., et al. 1997. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int. J. Syst. Microbiol. 47(4): 1188-1200. PMID:9336927.
132. Vandamme, P., Henry, D., Coenye, T., Nzula, S., Vancanneyt, M., LiPuma, J.J., et al. 2002. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol. Med. Microbiol. 33(2): 143-149. doi:10.1111/j.1574-695X.2002.tb00584.x. PMID:12052570.
133. Vanlaere, E., LiPuma, J.J., Baldwin, A., Henry, D., De Brandt, E., Mahenthiralingam, E., et al. 2008. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov., and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int. J. Syst. Evol. Microbiol. 58(7): 1580-1590. doi:10.1099/ijs.0. 65634-0. PMID:18599699.
134. Vanlaere, E., Baldwin, A., Gevers, D., Henry, D., De Brandt, E., LiPuma, J.J., et al. 2009. Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int. J. Syst. Evol. Microbiol. 59(1): 102-111. doi:10.1099/ ijs.0.001123-0. PMID:19126732.
135. Vermis, K., Brachkova, M., Vandamme, P., and Nelis, H. 2003. Isolation of Burkholderia cepacia complex genomovars from waters. Syst. Appl. Microbiol. 26(4): 595-600. doi:10.1078/ 072320203770865909. PMID:14666988.
136. Waldor, M.K., and Mekalanos, J.J. 1996. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science, 272(5270): 1910-1914. doi:10.1126/science.272.5270.1910. PMID:8658163.
137. Westwater, C., Kasman, L.M., Schofield, D.A., Werner, P.A., Dolan, J.W., Schmidt, M.G., and Norris, J.S. 2003. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47(4): 1301-1307. doi:10.1128/AAC. 47.4.1301-1307.2003. PMID:12654662.
138. Willner, D., Haynes, M.R., Furlan, M., Hanson, N., Kirby, B., Lim, Y.W., et al. 2011. Case studies of the spatial heterogeneity of DNA viruses in the cystic fibrosis lung. Am. J. Respir. Cell Mol. Biol. In press. doi:10.1165/rcmb.2011-0253OC. PMID:21980056.
139. Winstanley, C., Langille, M.G.I., Fothergill, J.L., Kukavica-Ibrulj, I., Paradis-Bleau, C., Sanschagrin, F., et al. 2009. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res. 19(1): 12-23. doi:10.1101/gr.086082.108. PMID:19047519.
140. Wright, A., Hawkins, C.H., Änggård, E.E., and Harper, D.R. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34(4): 349-357. doi:10.1111/j.1749-4486.2009.01973.x. PMID: 19673983.
141. Xu, K.D., Franklin, M.J., Park, C.-H., McFeters, G.A., and Stewart, P. S. 2001. Gene expression and protein levels of the stationary phase sigma factor, RpoS, in continuously-fed Pseudomonas aeruginosa biofilms. FEMS Microbiol. Lett. 199(1): 67-71. doi:10.1111/j. 1574-6968.2001.tb10652.x. PMID:11356569.
142. Xu, J., Hendrix, R.W., and Duda, R.L. 2004. Conserved translational frameshift in dsDNA bacteriophage tail assembly genes. Mol. Cell, 16(1): 11-21. doi:10.1016/j.molcel.2004.09.006. PMID:15469818.
143. Young, R., Wang, I.-N., and Roof, W.D. 2000. Phages will out: strategies of host cell lysis. Trends Microbiol. 8(3): 120-128. doi:10.1016/S0966-842X(00)01705-4. PMID:10707065.
144. Zafar, N., Mazumder, R., and Seto, D. 2002. CoreGenes: a computational tool for identifying and cataloging "core" genes in a set of small genomes. BMC Bioinformatics, 3(1): 12. doi:10. 1186/1471-2105-3-12. PMID:11972896.
145. Zhou, J., Chen, Y., Tabibi, S., Alba, L., Garber, E., and Saiman, L. 2007. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 51(3): 1085-1088. doi:10.1128/AAC.00954-06. PMID:17158942.